IDDI & Roche Identify DFS As Way Forward In Early Breast Cancer

Published on: 

Applied Clinical Trials

Commissioned by Roche Germany, IDDI has found data that suggests that it is appropriate to use disease-free survival as a surrogate for overall survival in trials in HER-2-positive breast cancer.  

To learn more about their findings, click here.